{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:03:40Z","timestamp":1789571020170,"version":"build-2803163510"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)\/GLP-1 receptor agonist tirzepatide have expanded from glucose-lowering therapy into cardiovascular medicine. In type 2 diabetes, several long-acting GLP-1RAs reduce major adverse cardiovascular events (MACE). SELECT extended this benefit to adults with established cardiovascular disease and overweight or obesity without diabetes, while SOUL demonstrated MACE reduction with oral semaglutide. SURPASS-CVOT established cardiovascular noninferiority of tirzepatide to dulaglutide but did not demonstrate superiority. Obesity-related heart failure with preserved ejection fraction (HFpEF) has emerged as a particularly responsive phenotype: semaglutide improves symptoms and physical function, whereas tirzepatide also reduces worsening heart failure events. FLOW further supports kidney and cardiovascular protection with semaglutide in type 2 diabetes and chronic kidney disease. Randomised human studies support effects on adiposity, haemodynamic burden, inflammation and cardiorenal outcomes, whereas endothelial, coronary microvascular and direct myocardial mechanisms remain less clinically validated. This Review integrates the current evidence, distinguishes randomised outcomes from observational and mechanistic signals, and provides a practical phenotype-directed treatment algorithm incorporating atherosclerotic cardiovascular disease, obesity, type 2 diabetes, chronic kidney disease, HFpEF, sodium\u2013glucose cotransporter 2 inhibitor use and patient-specific treatment constraints. Current practice should be guided by indication-specific outcome evidence rather than weight-loss magnitude or indirect cross-trial comparisons.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1926629","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:20:09Z","timestamp":1789568409000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiovascular protection beyond glucose lowering: GLP-1 receptor agonists and dual GIP\/GLP-1 receptor agonism in contemporary cardiology"],"prefix":"10.3389","volume":"13","author":[{"given":"Mingzhe","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, Siping City Central People\u2019s Hospital","place":["Siping, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"B4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.2337\/dc24-0764","article-title":"Semaglutide and cardiovascular outcomes by baseline HbA1c and change in HbA1c in people with overweight or obesity but without diabetes in SELECT","volume":"47","author":"Lingvay","year":"2024","journal-title":"Diabetes Care"},{"key":"B9","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield","year":"2024","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1016\/S0140-6736(24)00469-0","article-title":"Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials","volume":"403","author":"Butler","year":"2024","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1038\/s41591-023-02526-x","article-title":"Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial","volume":"29","author":"Borlaug","year":"2023","journal-title":"Nat Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.jacc.2024.06.001","article-title":"Efficacy of semaglutide by sex in obesity-related heart failure with preserved ejection fraction: STEP-HFpEF trials","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1093\/eurheartj\/ehae322","article-title":"Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials","volume":"45","author":"Shah","year":"2024","journal-title":"Eur Heart J"},{"key":"B16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer","year":"2025","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jacc.2024.11.001","article-title":"Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: sUMMIT CMR substudy","volume":"85","author":"Kramer","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/s41591-024-03374-z","article-title":"Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial","volume":"31","author":"Borlaug","year":"2025","journal-title":"Nat Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire","year":"2025","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1161\/CIRCULATIONAHA.125.074545","article-title":"Oral semaglutide and cardiovascular outcomes in people with type 2 diabetes, according to SGLT2i use: prespecified analyses of the SOUL randomized trial","volume":"151","author":"Marx","year":"2025","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1056\/NEJMoa2505928","article-title":"Cardiovascular outcomes with tirzepatide versus dulaglutide in type 2 diabetes","volume":"393","author":"Nicholls","year":"2025","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1001\/jamacardio.2026.0767","article-title":"Cardiorenal outcomes with tirzepatide compared with dulaglutide in patients with diabetes and cardiovascular disease: a post hoc analysis of the SURPASS-CVOT randomized clinical trial","volume":"11","author":"Nissen","year":"2026","journal-title":"JAMA Cardiology"},{"key":"B23","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41591-022-01707-4","article-title":"Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis","volume":"28","author":"Sattar","year":"2022","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4093\/dmj.2023.0277","article-title":"Glucagon-like peptide-1: new regulator in lipid metabolism","volume":"48","author":"Bu","year":"2024","journal-title":"Diabetes Metab J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/ehjcvp\/pvae093","article-title":"Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis","volume":"11","author":"Lin","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B26","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 Receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/j.jacc.2025.08.027","article-title":"Cardiovascular effects and tolerability of GLP-1 receptor agonists: a systematic review and meta-analysis of 99,599 patients","volume":"86","author":"Galli","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American diabetes association (ADA) and kidney disease: improving global outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1016\/j.cjca.2022.04.029","article-title":"2022 Canadian cardiovascular society guideline for use of GLP-1 receptor agonists and SGLT2 inhibitors for cardiorenal risk reduction in adults","volume":"38","author":"Mancini","year":"2022","journal-title":"Can J Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"6691","DOI":"10.1111\/dom.70080","article-title":"Lower risk of cardiovascular events in patients initiated on semaglutide 2.4\u2005mg in the real-world: results from the SCORE study (semaglutide effects on cardiovascular outcomes in people with overweight or obesity in the real world)","volume":"27","author":"Smolderen","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"4975","DOI":"10.1111\/dom.70686","article-title":"Lower risk of cardiovascular events in patients with clinical atherosclerotic cardiovascular disease who initiated semaglutide 2.4\u2005mg in the real-world: results from the SCORE\u2014clinical ASCVD study","volume":"28","author":"Nanna","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.jcmg.2024.10.004","article-title":"Allocation of semaglutide according to coronary artery calcium and BMI: applying the SELECT trial to MESA","volume":"18","author":"Razavi","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"key":"B36","doi-asserted-by":"publisher","first-page":"17562864241281903","DOI":"10.1177\/17562864241281903","article-title":"Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP\/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis","volume":"17","author":"Stefanou","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1111\/dom.70515","article-title":"Risk stratification using coronary artery calcium and potential benefit of semaglutide therapy: a cost-effectiveness modelling study","volume":"28","author":"Ponnana","year":"2026","journal-title":"Diabetes Obes Metab"},{"key":"B38","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1001\/jamainternmed.2025.7774","article-title":"Oral semaglutide and heart failure outcomes in persons with type 2 diabetes: a secondary analysis of the SOUL randomized clinical trial","volume":"186","author":"Pop-Busui","year":"2026","journal-title":"JAMA Intern Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"102777","DOI":"10.1016\/j.eclinm.2024.102777","article-title":"Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study","volume":"75","author":"Anson","year":"2024","journal-title":"eClinicalMed"},{"key":"B40","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/s41591-025-04102-x","article-title":"Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice","volume":"32","author":"Kr\u00fcger","year":"2026","journal-title":"Nat Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/ehf2.15205","article-title":"State of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age","volume":"12","author":"Rasalam","year":"2025","journal-title":"ESC Heart Fail"},{"key":"B42","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12933-025-02707-7","article-title":"Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF","volume":"24","author":"Luo","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/jcdd13040153","article-title":"Obesity and heart failure: introducing the theme","volume":"13","author":"Monitillo","year":"2026","journal-title":"J Cardiovasc Dev Dis"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.jacc.2024.08.023","article-title":"Atrial fibrillation and semaglutide effects in obesity-related heart failure with preserved ejection fraction: sTEP-HFpEF program","volume":"84","author":"Verma","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1001\/jama.2025.14092","article-title":"Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction","volume":"334","author":"Kr\u00fcger","year":"2025","journal-title":"JAMA"},{"key":"B46","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.cardfail.2024.10.448","article-title":"GLP-1 receptor agonist in nonobese patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction","volume":"31","author":"Khadke","year":"2025","journal-title":"J Card Fail"},{"key":"B47","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies","year":"2016","journal-title":"JAMA"},{"key":"B48","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"B49","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/eurjpc\/zwad050","article-title":"Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies","volume":"30","author":"Malavazos","year":"2023","journal-title":"Eur J Prev Cardiol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12933-023-01765-z","article-title":"Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial","volume":"22","author":"Sandsdal","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1111\/dom.15464","article-title":"Separate and combined effects of empagliflozin and semaglutide on vascular function: a 32-week randomized trial","volume":"26","author":"Vernstr\u00f8m","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B52","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1161\/ATVBAHA.124.321850","article-title":"Semaglutide improves myocardial perfusion and performance in a large animal model of coronary artery disease","volume":"45","author":"Stone","year":"2025","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1002\/ejhf.3644","article-title":"Cardioprotective effects of semaglutide on isolated human ventricular myocardium","volume":"27","author":"Krammer","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"B54","doi-asserted-by":"publisher","first-page":"101641","DOI":"10.1016\/j.molmet.2022.101641","article-title":"Glucagon-like peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction","volume":"66","author":"McLean","year":"2022","journal-title":"Mol Metab"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1529652","DOI":"10.3389\/fphar.2025.1529652","article-title":"Semaglutide attenuates myocardial ischemia-reperfusion injury by inhibiting ferroptosis of cardiomyocytes via activation of PKC-S100A9 axis","volume":"16","author":"Liu","year":"2025","journal-title":"Front Pharmacol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3390\/ph15060720","article-title":"Discrepancy between the actions of glucagon-like peptide-1 receptor ligands in the protection of the heart against ischemia reperfusion injury","volume":"15","author":"Ismaeil","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"B57","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.jacc.2024.04.064","article-title":"Liraglutide improves myocardial perfusion and energetics and exercise tolerance in patients with type 2 diabetes","volume":"84","author":"Chowdhary","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S2213-8587(24)00155-4","article-title":"Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials","volume":"12","author":"Apperloo","year":"2024","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e078242","DOI":"10.1136\/bmj-2023-078242","article-title":"Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study","volume":"385","author":"Simms-Williams","year":"2024","journal-title":"Br Med J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jacc.2023.05.048","article-title":"GLP-1 receptor agonist therapy with and without SGLT2 inhibitors in patients with type 2 diabetes","volume":"82","author":"Neves","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1016\/S2213-8587(22)00243-1","article-title":"Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial","volume":"10","author":"Heerspink","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1053\/j.ajkd.2025.09.010","article-title":"Glucagon-like peptide-1 receptor agonists and risk of Major adverse cardiovascular events in patients with CKD","volume":"87","author":"Yau","year":"2026","journal-title":"Am J Kidney Dis"},{"key":"B63","doi-asserted-by":"publisher","first-page":"Cd015849","DOI":"10.1002\/14651858.CD015849.pub2","article-title":"Glucagon-like peptide 1 (GLP-1) receptor agonists for people with chronic kidney disease and diabetes","volume":"2","author":"Natale","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e14292","DOI":"10.1111\/eci.14292","article-title":"Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: a systematic review and meta-analysis","volume":"54","author":"Saglietto","year":"2024","journal-title":"Eur J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","first-page":"e2555952","DOI":"10.1001\/jamanetworkopen.2025.55952","article-title":"Glucagon-like peptide-1 receptor agonists and prior Major adverse limb events in patients with diabetes","volume":"9","author":"Hsiao","year":"2026","journal-title":"JAMA Netw Open"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1007\/s00125-023-05988-3","article-title":"Incretins and microvascular complications of diabetes: neuropathy, nephropathy, retinopathy and microangiopathy","volume":"66","author":"Goldney","year":"2023","journal-title":"Diabetologia"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e074068","DOI":"10.1136\/bmj-2022-074068","article-title":"Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials","volume":"381","author":"Shi","year":"2023","journal-title":"Br Med J"},{"key":"B68","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1186\/s12933-025-02900-8","article-title":"Cardiovascular and renal outcomes of dual combination therapies with glucagon-like peptide-1 receptor agonists and sodium-glucose transport protein 2 inhibitors: a systematic review and meta-analysis","volume":"24","author":"Shokravi","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/s12933-025-02737-1","article-title":"Real-world effectiveness of adding newer generation GLP-1RA to SGLT2i in type 2 diabetes","volume":"24","author":"Chaiyakunapruk","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/ehjcvp\/pvaf014","article-title":"Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohort study","volume":"11","author":"Chen","year":"2025","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"B71","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad870","article-title":"2023 ESC guidelines for the management of acute coronary syndromes: developed by the task force on the management of acute coronary syndromes of the European Society of Cardiology (ESC)","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC guidelines for the management of chronic coronary syndromes","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"key":"B73","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1093\/eurheartj\/ehae508","article-title":"Obesity and cardiovascular disease: an ESC clinical consensus statement","volume":"45","author":"Koskinas","year":"2024","journal-title":"Eur Heart J"},{"key":"B74","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology joint committee on clinical practice guidelines","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2026.06.018","article-title":"Management of heart failure with preserved ejection fraction: 2026 ACC expert consensus decision pathway","author":"Kittleson","year":"","journal-title":"JACC"},{"key":"B76","doi-asserted-by":"publisher","first-page":"S216","DOI":"10.2337\/dc25-S010","article-title":"10. Cardiovascular disease and risk management: standards of care in diabetes\u20142026","volume":"49","year":"2025","journal-title":"Diabetes Care"},{"key":"B77","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","article-title":"Executive summary of the KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease: known knowns and known unknowns","volume":"105","author":"Levin","year":"2024","journal-title":"Kidney Int"},{"key":"B78","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.kint.2024.12.019","article-title":"GLP-1 receptor agonists and other incretin mimetics for diabetes and chronic kidney disease-a KDIGO commentary","volume":"107","author":"de Boer","year":"2025","journal-title":"Kidney Int"},{"key":"B79","doi-asserted-by":"publisher","first-page":"sfae250","DOI":"10.1093\/ckj\/sfae250","article-title":"Semaglutide-associated kidney injury","volume":"17","author":"Begum","year":"2024","journal-title":"Clin Kidney J"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1016\/j.jacc.2026.01.013","article-title":"Designing next-generation cardiometabolic outcome trials for obesity medicines","volume":"87","author":"Platz","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.1007\/s40618-025-02700-7","article-title":"Precision obesity medicine: a phenotype-guided framework for pharmacologic therapy across the lifespan","volume":"48","author":"Tuccinardi","year":"2025","journal-title":"J Endocrinol Invest"},{"key":"B82","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijcard.2023.03.054","article-title":"How cardiologists can manage excess body weight and related cardiovascular risk. An expert opinion","volume":"381","author":"Volpe","year":"2023","journal-title":"Int J Cardiol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1038\/s41591-025-03978-z","article-title":"A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults","volume":"31","author":"McGowan","year":"2025","journal-title":"Nat Med"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1926629\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:20:11Z","timestamp":1789568411000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1926629\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":83,"alternative-id":["10.3389\/fcvm.2026.1926629"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1926629","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"article-number":"1926629"}}